Halozyme Therapeutics HALO Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $1.51B+39.1% | $1.4B+37.6% | $1.24B+31.2% | $1.18B+35.0% | $1.08B+25.6% | ||
| $259.61M+44.6% | $228.77M+43.5% | $192.06M+13.2% | $186.24M+6.4% | $179.49M-3.2% | ||
| $1.25B+38.0% | $1.17B+36.4% | $1.05B+35.1% | $992.43M+42.1% | $904.82M+33.6% | ||
| 82.8%-0.7pp | 83.6%-0.7pp | 84.5%+2.5pp | 84.2%+4.2pp | 83.4%+4.9pp | ||
| $92.25M+23.4% | $81.49M+3.1% | $70.03M-12.4% | $71.24M-9.6% | $74.74M-3.6% | ||
| $222.61M+37.8% | $207.09M+34.2% | $172.31M+15.1% | $167.47M+16.5% | $161.56M+9.9% | ||
| $996.47M+105% | $927.61M+100.0% | $505.45M+7.5% | $496M+5.3% | $486.84M+0.7% | ||
| —— | —— | $737.4M+54.6% | $682.67M+69.8% | $597.47M+57.5% | ||
| $19.11M+5.5% | $18.13M+0.2% | $17.76M-5.4% | $17.98M-4.1% | $18.11M-3.3% | ||
| $15.97M-37.6% | $21.47M-9.6% | $26.3M+20.3% | $27.44M+36.0% | $25.58M+39.5% | ||
| —— | —— | $745.94M+55.4% | $692.13M+66.1% | $604.93M+54.3% | ||
| $154.53M+29.2% | $149.99M+32.7% | $150.45M+71.7% | $134.85M+69.8% | $119.57M+63.1% | ||
| —— | —— | $595.49M+51.7% | $557.28M+65.2% | $485.36M+52.2% | ||
| —— | —— | $4.75+57.3% | $4.37+69.4% | $3.76+55.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Halozyme Therapeutics's revenue?
- Halozyme Therapeutics (HALO) generated $1.5B in revenue over the trailing twelve months, up 39.1% year over year.
- Is Halozyme Therapeutics profitable?
- Halozyme Therapeutics reported $608.5M in net income over the trailing twelve months, a 47.9% net margin.
- What are Halozyme Therapeutics's profit margins?
- Gross margin is 82.8% and operating margin is 59.3%, with a 47.9% net margin.
- What is Halozyme Therapeutics's earnings per share?
- Halozyme Therapeutics's diluted EPS over the trailing twelve months is $4.91.
- Where does Halozyme Therapeutics's income statement data come from?
- Every line is extracted from Halozyme Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
